Managing congestion in heart failure with a remote monitoring device

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The MAGIC-HF clinical trial aims to improve the management of congestion in patients with heart failure with preserved ejection fraction (HFpEF) through daily remote monitoring. Participants will use the CardioMEMS™ device to measure pulmonary artery pressure and a smart scale to assess body water levels. This prospective, multi-center study will collect data over six months to evaluate the relationship between pressure and volume in managing fluid buildup. The goal is to enhance early detection of decompensation and optimize treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years of age or older
* Patients with HFpEF, who are hospitalized for acute decompensated heart failure and require treatment with intravenous (IV) diuretics.
* Signed informed consent.

Exclusion Criteria:

* Patients admitted with cardiogenic shock and/or those who required inotropic or vasopressor support.
* Had a history of cardiac transplantation or ventricular assist device (VAD) implantation.
* Had any implanted cardiac device (pacemaker, ICD, CRT-D.
* Had chronic kidney disease with creatinine clearance \< 20 ml/min.
* Had recent acute MI or CABG within 3 months.

Where it's running

• Otto von Guericke University, Faculty of Medicine
  Magdeburg, Saxony-Anhalt, Germany Recruiting

Study contacts

• Study coordinator: Tarek Bekfani, MD, MSc
• Email: tarek.bekfani@med.ovgu.de
• Phone: +49-391-67-14469

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Remote rehabilitation for HFpEF patients using telerehabilitation

  A home-based telerehabilitation program is being tested to see if it is safe and helpful for people with heart failure with preserved ejection fraction.

  Recruiting at 3 sites American Heart of Poland · Chrzanów and 2 other locations · NCT07918209

• EDG-15400 in adults with HFpEF: a phase 2 study

  This phase 2 study tests different doses of EDG-15400 against placebo in adults with HFpEF to see if it is safe and tolerable.

  Recruiting at 4 sites Phase 2 Edgewise Therapeutics, Inc. · Birmingham, Alabama and 27 other locations · NCT07795814

• Incretin therapy with tirzepatide for obesity-related HFpEF

  A 15-month study will test whether tirzepatide helps people with obesity and HFpEF by reducing plasma volume.

  Recruiting Phase 4 Columbia University · New York, New York · NCT07554638

• Boosted exercise with group coaching for HFpEF

  This trial tests a blended, guided exercise program with group coaching and remote monitoring to see if it helps older adults with HFpEF improve activity and health at a lower cost.

  Recruiting Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT07413198

• Exercise cardiac MRI for heart failure with preserved ejection fraction

  This study will try low-field exercise cardiac MRI to see if it can diagnose, describe, and predict risk in people with HFpEF compared with those who have non-cardiac breathlessness and healthy volunteers.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07401771

• HRS-1893 for heart failure with preserved ejection fraction

  This trial will test whether HRS-1893 is safe and tolerable in adults aged 40 and older who have heart failure with preserved ejection fraction.

  Recruiting Phase 2 Shandong Suncadia Medicine Co., Ltd. · Shanghai, Shanghai Municipality · NCT07269717

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.